Cumulative survival without hepatitis B virus reactivation
. | . | . | Cox proportional hazards regression analysis of individual factor . | . | . | ||
|---|---|---|---|---|---|---|---|
| Factor . | Patients with HBV reactivation, n = 9 . | Patients without HBV reactivation, n = 13 . | Hazard ratio . | 95% CI . | P . | ||
| Median age, y (range) | 42 (22-55) | 54 (24-76) | 0.97 | (0.93-1.02) | .21 | ||
| Sex, no. | .64 | ||||||
| Male | 6 | 6 | 1.39 | (0.35-5.61) | |||
| Female | 3 | 7 | 1.00 | - | |||
| Histology, no. | .91 | ||||||
| HD | 2 | 1 | 1.10 | (0.22-5.46) | |||
| NHL | 7 | 12 | 1.00 | - | |||
| HBeAg, no. | .93 | ||||||
| Positive | 3 | 10 | 1.06 | (0.26-4.26) | |||
| Negative | 6 | 3 | 1.00 | - | |||
| BCP variant, no. | .41 | ||||||
| Positive | 7 | 9 | 0.51 | (0.10-2.57) | |||
| Negative | 2 | 4 | 1.00 | - | |||
| PC variant, no. | .48 | ||||||
| Positive | 3 | 5 | 0.60 | (0.15-2.45) | |||
| Negative | 6 | 8 | 1.00 | - | |||
| HBV DNA, no. | .13 | ||||||
| Positive | 5 | 2 | 2.77 | (0.74-10.4) | |||
| Negative | 4 | 11 | 1.00 | - | |||
| Median HBV DNA level, pg/mL (range) | 45 (1-1410) | 138 (28-248) | 1.00 | (1.00-1.00) | .79 | ||
| HBV genotype, no. | .06 | ||||||
| C | 3 | 9 | 0.25 | (0.06-1.03) | |||
| B | 6 | 4 | 1.00 | - | |||
| Median intrahepatic cccDNA level, no. copies/cell (range) | 4.2 (0.1-75.56) | 0.22 (0-1.8) | 1.04 | (1.01-1.07) | .01 | ||
| Elevated serum baseline, no. | 2 | 3 | 1.27 | (0.25-6.38) | .77 | ||
| ALT | 1.00 | - | |||||
| Bilirubin, μM (range) | 12 (6-49) | 10 (6-49) | 1.02 | (0.97-1.08) | .47 | ||
| Chemotherapy regimen containing steroid | .77 | ||||||
| Yes | 7* | 12† | 1.36 | (0.17-11.1) | |||
| No | 2‡ | 1§ | 1.00 | - | - | ||
. | . | . | Cox proportional hazards regression analysis of individual factor . | . | . | ||
|---|---|---|---|---|---|---|---|
| Factor . | Patients with HBV reactivation, n = 9 . | Patients without HBV reactivation, n = 13 . | Hazard ratio . | 95% CI . | P . | ||
| Median age, y (range) | 42 (22-55) | 54 (24-76) | 0.97 | (0.93-1.02) | .21 | ||
| Sex, no. | .64 | ||||||
| Male | 6 | 6 | 1.39 | (0.35-5.61) | |||
| Female | 3 | 7 | 1.00 | - | |||
| Histology, no. | .91 | ||||||
| HD | 2 | 1 | 1.10 | (0.22-5.46) | |||
| NHL | 7 | 12 | 1.00 | - | |||
| HBeAg, no. | .93 | ||||||
| Positive | 3 | 10 | 1.06 | (0.26-4.26) | |||
| Negative | 6 | 3 | 1.00 | - | |||
| BCP variant, no. | .41 | ||||||
| Positive | 7 | 9 | 0.51 | (0.10-2.57) | |||
| Negative | 2 | 4 | 1.00 | - | |||
| PC variant, no. | .48 | ||||||
| Positive | 3 | 5 | 0.60 | (0.15-2.45) | |||
| Negative | 6 | 8 | 1.00 | - | |||
| HBV DNA, no. | .13 | ||||||
| Positive | 5 | 2 | 2.77 | (0.74-10.4) | |||
| Negative | 4 | 11 | 1.00 | - | |||
| Median HBV DNA level, pg/mL (range) | 45 (1-1410) | 138 (28-248) | 1.00 | (1.00-1.00) | .79 | ||
| HBV genotype, no. | .06 | ||||||
| C | 3 | 9 | 0.25 | (0.06-1.03) | |||
| B | 6 | 4 | 1.00 | - | |||
| Median intrahepatic cccDNA level, no. copies/cell (range) | 4.2 (0.1-75.56) | 0.22 (0-1.8) | 1.04 | (1.01-1.07) | .01 | ||
| Elevated serum baseline, no. | 2 | 3 | 1.27 | (0.25-6.38) | .77 | ||
| ALT | 1.00 | - | |||||
| Bilirubin, μM (range) | 12 (6-49) | 10 (6-49) | 1.02 | (0.97-1.08) | .47 | ||
| Chemotherapy regimen containing steroid | .77 | ||||||
| Yes | 7* | 12† | 1.36 | (0.17-11.1) | |||
| No | 2‡ | 1§ | 1.00 | - | - | ||
HD indicates Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; HBeAg, hepatitis B e antigen; BCP, basic core promoter T1762/A1764; PC, precore variant A1896; cccDNA, covalently closed circular DNA; ALT, alanine transaminase; and -, not applicable.
For CEOP (cyclophosphamide, epirubicin, vincristine, prednisolone), n = 4; Stanford V (adriamycin, vinblastine, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone), n = 2; and COPP (cyclophosphamide, vincristine, procarbazine, prednisolone), n = 1
For CEOP, n = 5; COPP, n = 2; CVP (cyclophosphamide, vincristine, prednisolone), n = 2; DHAP (cisplatin, cytarabine, dexamethasone), n = 2; and FND (fludarabine, mitoxantrone, dexamethasone), n = 1
IMVP16 (ifosfamide, methotrexate, etoposide), n = 1
ABVD (adriamycin, bleomycin, vinblastine, dacarbazine), n = 2